Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Clarity Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Clarity’s prostate cancer imaging agent gets FDA ‘Fast Track’ status
Experts
Tru Datt: When safe havens fail, head on down to the niche corners of the ASX
News
Closing Bell: Local tech talent steps up ahead of blockbuster inflation week
Experts
Tru Datt: Ride the dip with these smart ASX stocks
Health & Biotech
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Miners, Energy stocks sink ASX; Nanovue up 60pc on EyeFly3D deal
News
Market Highlights: ASX braces for dip, BHP scraps Anglo bid, and China lifts Aussie beef ban
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Experts
Tru Datt: It’s a pretty good time to call yourself an ASX small cap
Health & Biotech
ScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reports
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Lithium stocks flash green; suitor lobs bid for Sihayo Gold
Health & Biotech
ASX Health Stocks: Clarity Pharma says its prostate cancer treatment has achieved ‘complete response’
Experts
MoneyTalks: Pointsbet exits US business, will gain market share in Australia says broker
Health & Biotech
